<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04741295</url>
  </required_header>
  <id_info>
    <org_study_id>SZ-2021-ADE1</org_study_id>
    <nct_id>NCT04741295</nct_id>
  </id_info>
  <brief_title>Low Molecular Weight Heparin on the Adenomyosis Patients'IVF-ET Outcome</brief_title>
  <official_title>To Study the Effect of Low Molecular Weight Heparin on the Adenomyosis Patients'Outcome of in Vitro Fertilization-embryo Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In assisted reproductive technology, adenomyosis patients are characterized by lower clinical&#xD;
      pregnancy rate, lower implantation rate and higher abortion rate. The purpose of this study&#xD;
      is to explore whether low molecular weight heparin can reduce the abortion rate of&#xD;
      adenomyosis patients in frozen thawed embryo transfer cycles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early spontaneous abortion rate</measure>
    <time_frame>Within three months after frozen embryo transfer</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Adenomyosis</condition>
  <condition>Assisted Reproductive Technology</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Adenomyosis patients in control group have normal luteal progesterone support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low molecular weight heparin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adenomyosis patients in Low molecular weight heparin group have Low molecular weight heparin in addition to normal luteal progesterone support.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low molecular weight heparin</intervention_name>
    <description>Patients with adenomyosis were treated with low molecular weight heparin after frozen embryo transfer in addition to routine luteal support.</description>
    <arm_group_label>Low molecular weight heparin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The basal serum level of FSH was less than 10 IU / L&#xD;
&#xD;
          2. Diagnosed with adenomyosis by ultrasound&#xD;
&#xD;
          3. The first frozen thawed embryo transfer cycle, by hormone replacement protocol&#xD;
&#xD;
          4. Transfer at least one high quality frozen embryo;&#xD;
&#xD;
          5. Patients agreed to use low molecular weight heparin after FET, and they were able to&#xD;
             sign informed consent in person.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With abnormal karyotype;&#xD;
&#xD;
          2. Accompanied with other uterine diseases: intrauterine adhesion, intramural myoma,&#xD;
             moderate to severe endometriosis, congenital uterine malformation, endometrial&#xD;
             tuberculosis, thin endometrium &lt; 8mm on the day of transformation, etc;&#xD;
&#xD;
          3. PCOS, RIF patients;&#xD;
&#xD;
          4. There are indications of conventional anticoagulation or antiplatelet therapy, such as&#xD;
             antiphospholipid syndrome, autoimmune diseases, coagulation dysfunction, etc;&#xD;
&#xD;
          5. There were contraindications to hormone replacement therapy and low molecular weight&#xD;
             heparin;&#xD;
&#xD;
          6. Participating in other clinical studies;&#xD;
&#xD;
          7. Unable to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reproductive Medicine Center, The affiliated Drum Towel Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanjing University</investigator_affiliation>
    <investigator_full_name>Li-jun Ding</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

